mTOR Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4470333
  • Report
  • 124 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Astrazeneca PLC
  • Eli Lilly & Company
  • MORE
The mechanistic/mammalian target of rapamycin (mTOR) is a serine threonine protein kinase, that belongs to the phosphatidylinositol-3-kinase-related kinase family. Molecules in this family have more than 2,500 amino acids, and they harbor a kinase domain at their C-terminals. It has been observed that the increasing prevalence of cancer along with its high healthcare cost, globally, has been driving the growth of mTOR inhibitors pipeline. For instance, the number of people living beyond cancer diagnosis reached around 14.5 million in 2014 and is expected to increase to 19 million, by 2024. In 2010, approximately $125 million was spent on cancer care in the U.S., and it is expected to reach $156 million, by 2020.

Other factors strengthening the mTOR inhibitors pipeline include smoking, obesity unhygienic food, and allergy. The study analyzed that mTOR inhibitors therapeutics pipeline comprises approximately 30 drug candidates in different stages of development.

Insights on Pipeline Segments:

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.

Positive Clinical Results of mTOR Inhibitors Therapeutics Candidates

The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F. Hoffman-La-Roche AG has developed a drug candidate, ipatasertib, that acts as mTOR inhibitors. The Phase II clinical results (Study ID: NCT02162719) of the drug candidate were published in the Lancet Oncology journal. It has been observed that progression-free survival was longer in patients who received ipatasertib as compared in those who received placebo.

Technological Advancements for mTOR Inhibitors Therapeutics Drug Development

Most of the companies are developing innovative technologies for the synthesis or production of mTOR inhibitors. For instance, PHusis Therapeutics Inc. is using its computational modeling platform namely, PHuDock, that identify inhibitors of proteins which promotes the growth of cancer cells. Using PHuDock, X-ray structural information and surface plasmon resonance spectroscopic measurements of selected drug-like molecules, PHusis is rapidly and efficiently identifying agents involving toxicity studies, that selectively inhibit the activity of a number of these cancers driving proteins. PHuDock is applied to lead identification and optimization, as well as to predict the compounds off-target properties and toxicity, therefore delivering novel and highly effective agents with low toxicity.

These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk of toxicity, and relative to traditional approaches. Thus, these technological advancements act as a key driver for the pipeline growth.

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astrazeneca PLC
  • Eli Lilly & Company
  • MORE
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 by Industry Participant
2.2.2 by Company Type

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.2.1 Increasing Prevalence of Cancer and Rising Healthcare Cost
4.2.2 Technical Advancements
4.3 Key Barrier
4.3.1 Safety Concerns and Risk factors
4.4 mTOR Inhibitor Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

5. mTOR Inhibitor Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III
5.1.1 Ipatasertib
5.1.1.1 Clinical trials
5.1.1.2 Clinical results
5.1.1.3 Strategic developments
5.1.2 X
5.1.2.1 Clinical trials
5.2 Phase II
5.2.1 LY3023414
5.2.1.1 Clinical trials
5.2.2 X
5.2.2.1 Pre-Clinical studies
5.2.2.2 Clinical trials
5.2.2.3 Clinical results
5.2.2.4 Others
5.2.3 X
5.2.3.1 Clinical trials
5.2.3.2 Strategic developments
5.2.4 X
5.2.4.1 Clinical trials
5.2.4.2 Clinical results
5.2.4.3 Strategic developments
5.2.5 X
5.2.5.1 Clinical trials
5.2.5.2 Strategic developments
5.2.5.3 Grant
5.2.5.4 Technology
5.2.6 X
5.2.6.1 Clinical trials
5.2.6.2 Designation
5.2.7 X
5.2.7.1 Clinical trials
5.2.7.2 Clinical results
5.2.8 X
5.2.8.1 Pre-Clinical Studies
5.2.8.2 Clinical trials
5.2.8.3 Clinical results
5.2.8.4 Strategic developments
5.2.8.5 Designation
5.2.8.6 Grant
5.3 Phase I
5.3.1 VDC597
5.3.2 X
5.3.2.1 Clinical trials
5.4 Pre-Clinical
5.4.1 VPE001
5.4.1.1 Strategic developments
5.4.2 X
5.4.2.1 Pre-Clinical studies
5.4.2.2 Others
5.4.3 X
5.4.3.1 Technology
5.4.3.2 Strategic developments
5.4.4 X
5.4.4.1 Technology
5.4.5 X
5.4.6 X
5.4.6.1 Technology
5.4.6.2 Designation
5.4.7 X
5.4.7.1 Others
5.4.7.2 Technology
5.4.8 X
5.4.8.1 Pre-Clinical studies
5.4.8.2 Strategic developments
5.4.8.3 Technology
5.5 Discovery
5.5.1 VEA005
5.5.1.1 Strategic developments
5.5.2 X
5.5.2.1 Strategic developments
5.5.3 X
5.5.3.1 Strategic developments
5.5.4 X
5.5.4.1 Strategic developments
5.5.5 X
5.5.5.1 Strategic developments
5.5.5.2 Technology
5.5.6 X
5.5.6.1 Others
5.5.7 X
5.5.7.1 Technology
5.6 Unknown Phase
5.6.1 Non-Steroidal Small Molecule Drug
5.7 Discontinued

6. Clinical Trials Analysis
6.1 Clinical Trials by Region for mTOR Inhibitors Therapeutics Pipeline Analysis 2017
6.2 Clinical Trials by Trial Status for mTOR Inhibitors Therapeutics Pipeline Analysis 2017

7. Competitive Landscape
7.1 Key Players Benchmarking for mTOR inhibitors Therapeutics Pipeline
7.2 SWOT Analysis of mTOR inhibitor Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Eli Lilly & Company
8.1.1 Business Overview
8.1.2 Product & Service Offerings
8.2 AstraZeneca Plc
8.2.1 Business Overview
8.2.2 Product & Service Offerings
8.3 Company 3
8.3.1 Business Overview
8.3.2 Product & Service Offerings
8.4 Company 4
8.4.1 Business Overview
8.4.2 Product & Service Offerings
8.5 Company 5
8.5.1 Business Overview
8.5.2 Product & Service Offerings
8.6 Company 6
8.6.1 Business Overview
8.6.2 Product & Service Offerings
8.7 Company 7
8.7.1 Business Overview
8.7.2 Product & Service Offerings
8.8 Company 8
8.8.1 Business Overview
8.8.2 Product & Service Offerings
8.9 Company 9
8.9.1 Business Overview
8.9.2 Product & Service Offerings
8.1 Company 10
8.10.1 Business Overview
8.10.2 Product & Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Mtor Therapeutics, by Company (2017)
Table 2 Description of Ipatasertib
Table 3 Clinical Trials of Ipatasertib
Table 4 Description of X
Table 5 Clinical Trials of X
Table 6 Description of LY3023414
Table 7 Clinical Trials of LY3023414
Table 8 Description of X
Table 9 Clinical Trials of X
Table 10 Description of X
Table 11 Description of X
Table 12 Clinical Trials of X
Table 13 Description of X
Table 14 Clinical Trials of X
Table 15 Description of X
Table 16 Clinical Trials of X
Table 17 Description of X
Table 18 Clinical Trials of X
Table 19 Description of X
Table 20 Clinical Trials of X
Table 21 Description of VDC597
Table 22 Description of X
Table 23 Clinical Trials of X
Table 24 Description of VPE001
Table 25 Description of X
Table 26 Description of X
Table 27 Description of X
Table 28 Description of X
Table 29 Description of X
Table 30 Description of X
Table 31 Description of X
Table 32 Description of VEA005
Table 33 Description of X
Table 34 Description of X
Table 35 Description of X
Table 36 Description of X
Table 37 Description of X
Table 38 Description of X
Table 39 Description of Non-Steroidal Small Molecule Drug
Table 40 Description of Discontinued Drugs
Table 41 Eli Lilly & Company - at a Glance
Table 42 Astrazeneca Plc - at a Glance
Table 43 Company 3 - at a Glance
Table 44 Company 4 - at a Glance
Table 45 Company 5 - at a Glance
Table 46 Company 6 - at a Glance
Table 47 Company 7 - at a Glance
Table 48 Company 8 - at a Glance
Table 49 Company 9 - at a Glance
Table 50 Company 10 - at a Glance

List of Figures
Fig 1 Research Methodology
Fig 2 Split of Primary andSecondary Research
Fig 3 Breakdown of Primary Research by Industry Participant
Fig 4 Breakdown of Primary Research by Company Type
Fig 5 Cell Signaling Pathways
Fig 6 Gene Related To Mtor
Fig 7 Mtor Inhibitor Therapeutics Under Development (2017)
Fig 8 Mtor Inhibitor Therapeutics Pipeline Split, by Molecule Type (2017)
Fig 9 Mtor Therapeutic Pipeline Split, by Route of Administration (2017)
Fig 10 Breakdown of Clinical Trials, by Region
Fig 11 Breakdown of Clinical Trials, by Trial Status
Fig 12 Key Players Benchmarking
Fig 13 Swot Analysis
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astrazeneca PLC
  • Eli Lilly & Company
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll